ATE495743T1 - Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten - Google Patents

Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Info

Publication number
ATE495743T1
ATE495743T1 AT07857236T AT07857236T ATE495743T1 AT E495743 T1 ATE495743 T1 AT E495743T1 AT 07857236 T AT07857236 T AT 07857236T AT 07857236 T AT07857236 T AT 07857236T AT E495743 T1 ATE495743 T1 AT E495743T1
Authority
AT
Austria
Prior art keywords
treatment
degenerational
inflammatory diseases
triazolopyridine compounds
compounds
Prior art date
Application number
AT07857236T
Other languages
German (de)
English (en)
Inventor
Andrew Burritt
Paul John Edwards
Wolfgang Schmidt
Veronique Birault
Friedrich Erich Karl Kroll
Xueliang Tao
Martin James Inglis Andrews
Sebastien Laurent Xavier Martina
Original Assignee
Galapagos Nv
Andrew Burritt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Andrew Burritt filed Critical Galapagos Nv
Application granted granted Critical
Publication of ATE495743T1 publication Critical patent/ATE495743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07857236T 2006-12-01 2007-11-30 Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten ATE495743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86814406P 2006-12-01 2006-12-01
PCT/EP2007/063106 WO2008065198A1 (en) 2006-12-01 2007-11-30 Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE495743T1 true ATE495743T1 (de) 2011-02-15

Family

ID=38983774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07857236T ATE495743T1 (de) 2006-12-01 2007-11-30 Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Country Status (6)

Country Link
US (1) US7977352B2 (enExample)
EP (1) EP2086540B8 (enExample)
JP (1) JP2010511018A (enExample)
AT (1) ATE495743T1 (enExample)
DE (1) DE602007012133D1 (enExample)
WO (1) WO2008065198A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EP2254887B9 (en) 2008-02-22 2013-05-29 Actelion Pharmaceuticals Ltd. Oxazolidinone derivatives
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
BRPI0920895A8 (pt) 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
KR101667066B1 (ko) 2008-10-10 2016-10-17 액테리온 파마슈티칼 리미티드 옥사졸리디닐 항생제
CN102459258B (zh) 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
MX2016002764A (es) 2013-09-05 2016-05-26 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos.
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US10815231B2 (en) 2016-06-29 2020-10-27 West China Hospital, Sichuan University [1,2,4] triazolo [1,5-a] pyridine derivative and crystalline form thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018049089A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
JP7117293B2 (ja) 2016-09-16 2022-08-12 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Ｔｒａｆ６阻害剤
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
KR102849449B1 (ko) 2017-11-14 2025-08-21 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
TWI689510B (zh) 2017-12-18 2020-04-01 美商必治妥美雅史谷比公司 4-氮雜吲哚化合物
ES2977657T3 (es) 2017-12-19 2024-08-28 Bristol Myers Squibb Co Compuestos de 6-azaindol
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP7597709B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
CN114126713B (zh) 2019-05-09 2023-12-08 百时美施贵宝公司 经取代的苯并咪唑酮化合物
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
WO2025042408A1 (en) * 2023-08-18 2025-02-27 Schrödinger, Inc. Methods of treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1543008B1 (en) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US20080033006A1 (en) 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
TW200804386A (en) 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
JP2010511019A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物

Also Published As

Publication number Publication date
EP2086540B1 (en) 2011-01-19
EP2086540A1 (en) 2009-08-12
JP2010511018A (ja) 2010-04-08
WO2008065198A1 (en) 2008-06-05
DE602007012133D1 (de) 2011-03-03
US7977352B2 (en) 2011-07-12
US20090105242A1 (en) 2009-04-23
EP2086540B8 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200801997A1 (ru) Новые соединения
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties